MedPath

Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis

Not Applicable
Recruiting
Conditions
Schizophrenia Disorders
Treatment Resistant Hallucinations
Registration Number
NCT07091344
Lead Sponsor
Fundació Sant Joan de Déu
Brief Summary

This study aims to evaluate the relationship between cognitive, metacognitive and social cognition variables in patients with psychosis undergoing VR-based Avatar Therapy for the treatment of auditory hallucinations. In addition to the primary intervention, participants will be assessed using validated tools for emotion recognition, attributional style, theory of mind, neurocognition, and metacognition. The study also explores the potential role of trauma as a predisposing factor. Assessments will be conducted at four time points: screening (week 0), baseline (week 12), intervention period (weeks 12-24), and post-therapy follow-up (week 24). By investigating these variables, this study seeks to better understand their impact on treatment outcomes and contribute to the development of personalized therapeutic approaches.

Detailed Description

This interventional study investigates the impact of cognitive, metacognitive, and social cognition variables on the outcomes of VR-based Avatar Therapy for auditory hallucinations in patients with psychosis. Participants will be assessed at four key time points: screening (week 0), baseline (week 12), during the intervention (weeks 12-24), and post-therapy (week 24).

The intervention consists of 7 individual VR-based Avatar Therapy sessions delivered over 12 weeks. The therapy uses virtual reality to externalize and reframe distressing auditory hallucinations, helping participants develop more adaptive responses.

In addition to evaluating the therapy's effectiveness, the study incorporates validated tools to measure:

Social Cognition: Emotional recognition (Test de Reconocimiento Emocional), attributional style (AIHQ), theory of mind (Hinting Task), and social perception (SFRT-2).

Metacognition: Insight and cognitive monitoring using the BCIS and CBQ. Cognition: Neuropsychological functions, including attention, flexibility, and memory (SCIP, Stroop, TMT, and Vocabulary WAIS).

Trauma as a predisposing factor: Using the Childhood Trauma Questionnaire (CTQ).

By examining these variables, the study aims to deepen the understanding of their influence on treatment outcomes and inform the development of personalized therapeutic approaches for psychosis.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria

**

  • Adults aged 18 years or older.
  • Diagnosis of schizophrenia spectrum disorder according to DSM-5 criteria.
  • Experience of persistent auditory hallucinations for at least 3 months (PANSS hallucination score ≥ 3).
  • Stable medication dosage for at least 4 weeks prior to recruitment.
  • Fluent in the spoken language of the study site (Spanish).
  • Able to provide informed consent.
  • Regular psychiatric follow-up care.

**

Exclusion Criteria

**

  • Inability to identify a dominant voice for Avatar Therapy intervention.
  • Intellectual disability based on medical history.
  • Active substance abuse.
  • Central nervous system injury or neurological disorders affecting cognitive performance.
  • Severe visual impairment that precludes the use of VR technology.
  • Aversion to virtual reality or prior experience of simulator sickness.
  • Current suicidal ideation or risk.
  • Lack of cooperation or inability to comply with study procedures.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Change in Executive Functioning ScoreWeek 0, Week 12, Week 24.

Change in Executive Functioning Score Executive functioning assessed with the Wisconsin Card Sorting Test (WCST). Outcomes include number of categories completed (0-6; higher = better) and number of perseverative errors (no fixed maximum; lower = better). The task ends when the participant completes 6 categories or after all 128 cards are placed.

Change in Theory of Mind ScoreWeek 0, Week 12, Week 24

Ability to infer others' intentions measured by the Hinting Task. Score range: 0-6; higher scores = better Theory of Mind.

Change in Metacognition ScoreWeek 0, Week 12, Week 24

Cognitive insight measured by the Beck Cognitive Insight Scale (BCIS): Self-reflectiveness (0-27; higher = better) and Self-certainty (0-21; higher = worse).

Change in Global Cognitive Performance ScoreWeek 0, Week 12, Week 24

Global cognition assessed with the Screen for Cognitive Impairment in Psychiatry (SCIP). Total score range: 0-75; higher = better cognitive performance.

Change in Emotion Recognition ScoreWeek 0, Week 12, Week 24

Change in participants' ability to recognize basic emotions using the Faces Test. Score range: 0-20; higher scores = better emotion recognition.

Change in Attributional Style ScoreWeek 0, Week 12, Week 24

Attributional style in ambiguous social situations assessed with the Ambiguous Intentions Hostility Questionnaire (AIHQ). Score range: 0-100; higher scores = greater hostile attribution/conviction.

Change in Cognitive Flexibility ScoreWeek 0, Week 12, Week 24

Mental flexibility assessed with the Trail Making Test, Part B. Outcome: time in seconds (maximum 300 seconds); lower times = better performance.

Change in Working Memory ScoreWeek 0, Week 12, Week 24

Working memory assessed by the WAIS-IV Digit Span. Scaled score range: 1-19; higher scores = better performance.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Fundació Sant Joan de Déu - Unitat de Recerca del Parc Sanitari Sant Joan de Déu

🇪🇸

Barcelona, Catalonia, Spain

Fundació Sant Joan de Déu - Unitat de Recerca del Parc Sanitari Sant Joan de Déu
🇪🇸Barcelona, Catalonia, Spain
Susana Ochoa, PhD
Principal Investigator
Luciana Díaz-Cutraro, PhD
Contact
+34 93 600 97 51
luciana.diaz@sjd.es
Luciana Diaz-Cutraro, PhD
Sub Investigator
Marina Peniza-Soriano, Master degree
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.